Thumbnail Image
Item

Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis

Kulkarni, Tejaswini
; 
Criner, Gerard J.
; 
Kass, Daniel J.
; 
Rosas, Ivan O.
; 
Scholand, Mary Beth
; 
Dilling, Daniel F.
; 
Summer, Ross
; 
Duncan, Steven R.
Citations
Altmetric:
Genre
Journal article
Date
2024-03-20
Advisor
Committee member
Group
Department
Thoracic Medicine and Surgery
Subject
Acute exacerbation of idiopathic pulmonary fibrosis
 Autoantibody reduction
 Clinical trial
 Idiopathic pulmonary fibrosis
 Protocol
Permanent link to this record
https://scholarshare.temple.edu/handle/20.500.12613/11864
Collections
Faculty/Researcher Works
Show all metadata
Files
Thumbnail Image
Criner-JournalArticle-2024-03.pdf
Adobe PDF, 922.16 KB
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1186/s12890-024-02957-3
Abstract
Background Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) affect a significant proportion of patients with IPF. There are limited data to inform therapeutic strategies for AE-IPF, despite its high mortality. We discuss the rationale and design of STRIVE-IPF, a randomized, multi-center, open-label Phase IIb clinical trial to determine the efficacy of combined therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIG), in comparison to treatment as usual (TAU), among patients with acute IPF exacerbations. Methods The STRIVE-IPF trial will randomize 51 patients among five sites in the United States. The inclusion criteria have been designed to select a study population with AE-IPF, as defined by American Thoracic Society criteria, while excluding patients with an alternative cause for a respiratory decompensation. The primary endpoint of this trial is six-month survival. Secondary endpoints include supplement oxygen requirement and six-minute walk distance which will be assessed immediately prior to treatment and after completion of therapy on day 19, as well as at periodic subsequent visits. Discussion The experimental AE-IPF therapy proposed in this clinical trial was adapted from treatment regimens used in other antibody-mediated diseases. The regimen is initiated with TPE, which is expected to rapidly reduce circulating autoantibodies, followed by rituximab to reduce B-cells and finally IVIG, which likely has multiple effects, including affecting feedback inhibition of residual B-cells by Fc receptor occupancy. We have reported potential benefits of this experimental therapy for AE-IPF in previous anecdotal reports. This clinical trial has the potential to profoundly affect current paradigms and treatment approaches to patients with AE-IPF.
Description
Citation
Kulkarni, T., Criner, G.J., Kass, D.J. et al. Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis. BMC Pulm Med 24, 143 (2024). https://doi.org/10.1186/s12890-024-02957-3
Citation to related work
Springer Science and Business Media
Has part
BMC Pulmonary Medicine, Vol. 24, Iss. 1
ADA compliance
Embedded videos
License
Attribution CC BY
cb